

# Kidney Cancer Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage: \_\_0 \_\_I \_\_II \_\_III \_\_IV \_\_Recurrent

Line of Treatment: \_\_Adjuvant/Post-Op \_\_First Line \_\_Second Line \_\_Third Line \_\_Third Line +

ECOG Performance Status: \_\_0\_\_1\_\_2\_\_3\_\_4

Biomarker:

Prior therapy: \_\_\_\_\_

Renal cancer risk\*: \_\_Poor risk \_\_Intermediate risk \_\_Good risk

---

## Metastatic | First line therapy (1<sup>st</sup> line) | Clear Cell and Non-clear Cell

Pazopanib (Votrient)

Sunitinib (Sutent)

Temezirolimus (Torisel)

---

## Metastatic | Second line therapy (2<sup>nd</sup> line) | Clear Cell

Axitinib (Inlyta)

Cabozantinib (Cabometyx)

Nivolumab (Opdivo)

Sorafenib (Nexavar)

\*Risk factors (Good risk = no risk factors, Intermediate risk = 1 or 2 risk factors, Poor risk = 3 or more risk factors):

- High lactate dehydrogenase (LDH) level, greater than 1.5 times the upper limit of normal
- High blood calcium level, corrected level greater than 10 mg/dL
- Anemia
- 2 or more sites of organ metastasis
- Less than a year from original diagnosis to the need for systemic treatment
- Karnofsky performance status less than or equal to 70 (at least able to perform self-care activities, up and about greater than 50% of waking hours)

